RAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest Update

RAPT Therapeutics, Inc. (NASDAQ:RAPT) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,720,000 shares, an increase of 25.5% from the November 30th total of 1,370,000 shares. Based on an average trading volume of 2,800,000 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently bought and sold shares of RAPT. Bank of New York Mellon Corp grew its stake in shares of RAPT Therapeutics by 24.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after buying an additional 22,175 shares in the last quarter. Los Angeles Capital Management LLC raised its position in RAPT Therapeutics by 66.2% during the second quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares during the period. Acadian Asset Management LLC raised its position in RAPT Therapeutics by 4,183.3% during the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares during the period. Federated Hermes Inc. lifted its stake in shares of RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after purchasing an additional 520,368 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of RAPT Therapeutics by 108.1% in the 2nd quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock worth $622,000 after purchasing an additional 105,900 shares during the period. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 2.5 %

NASDAQ RAPT traded down $0.04 on Tuesday, reaching $1.58. The company had a trading volume of 2,746,637 shares, compared to its average volume of 1,366,551. The firm’s 50 day moving average price is $1.50 and its 200 day moving average price is $2.15. RAPT Therapeutics has a 12 month low of $0.79 and a 12 month high of $27.35. The stock has a market capitalization of $55.23 million, a PE ratio of -0.57 and a beta of 0.07.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, research analysts expect that RAPT Therapeutics will post -2.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $8.00 to $2.00 in a report on Monday, November 11th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Thursday, December 26th. Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.56.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.